WELLESLEY, Mass., March 18, 2021 /PRNewswire/ -- Ampersand Capital Partners announced a minority investment in Magritek, a global leader in benchtop and portable NMR instruments for life sciences and other industries. Founded in 2004, Magritek is a New Zealand company with operations in Aachen, Germany, Philadelphia, PA, and Wellington, NZ. Magritek's flagship Spinsolve benchtop NMR instruments provide resolution and sensitivity previously unavailable at the laboratory benchtop, bringing the power of NMR spectroscopy to laboratories and researchers worldwide.
Dave Patteson, Partner at Ampersand, stated "We are very excited to make this investment in Magritek, the dominant provider of lab-based NMR systems for discovery chemistry and reaction monitoring. Magritek's recent product introductions will further expand the market opportunity in flow chemistry and bioprocess monitoring, and we look forward to helping the Company grow."
Andrew Coy, CEO at Magritek, stated "We are delighted to have Ampersand Capital Partners join the shareholders of Magritek and helping us on our journey to bring the power of NMR spectroscopy to all chemists and scientists working at the laboratory bench."